5 Reasons Chasing COVID-19 Vaccine Stocks Is a Bad Idea
November has been a big month for the stock market. We've watched the residents of five states pass cannabis legalization initiatives or amendments, and elected the 46th President of the United States, Democrat Joe Biden.
But the real buzz is how we began the week, with Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) announcing the first interim analysis of their phase 3 study of BNT162b2 as a treatment for the SARS-CoV-2 virus, which is responsible for the coronavirus disease 2019 (COVID-19). The U.S. has tallied more than 10 million COVID-19 cases, which have led to 238,000 deaths, as of Nov. 9.
Image source: Getty Images.
Source Fool.com
